BT is developing novel and advanced products for two major medical indications in multi-hundred million-dollar markets. The Company’s mission is to become a leader in the development of obstetric pharmaceuticals, to improve healthcare delivery for patients, doctors and hospitals, and to provide an attractive return on investment for its shareholders and benefits for its strategic partners. Longer term, the
Company intends to apply its technology to additional lucrative markets such as veterinary obstetrics and to develop products for more OB/Gyn indications.
BT is further augmented by highly esteemed scientific leaders in obstetrics in Europe and the U.S.: Prof. Robert L. Goldenberg, Co-Director of the Center for Research in Women’s Health at the University of Alabama (UAB) and formerly the Chairman of the Department of Obstetrics and Gynecology; Prof. Phillip Robert Bennett, MD, PhD, FRCOG, a Professor in Obstetrics and Gynaecology at the Imperial College School of Medicine, Institute of Obstetrics; Prof. Emile Papiernik, Chairman of the Department of Obstetrics and Gynecology at the Hôpital Cochin, Paris; and Dr. Joseph Blankstein, the Chairman of the department of obstetrics and Gynecology at Mount Sinai Hospital Medical Center in Chicago, Illinois. [CV’s available upon request.